{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:29:18Z","timestamp":1784867358458,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic phase-chronic myeloid leukemia (CP-CML) in Qatar presents unique epidemiological and clinical challenges compared with those in the Western population, including nearly half of the affected patients being under 40 years of age. Additionally, the high prevalence of cardiovascular comorbidities in this region significantly influences treatment decisions. This position statement presents an evaluation of the therapeutic role of asciminib in patients previously treated with two or more tyrosine kinase inhibitors and its relevance within Qatar\u2019s healthcare system. Studies have demonstrated asciminib\u2019s superior efficacy in achieving higher rates of major molecular response than bosutinib. Furthermore, compared with ponatinib, asciminib offers a favorable cardiovascular safety profile, making it a preferred option for patients at risk of cardiovascular complications. Cost-effectiveness analyses further support its adoption as a viable treatment alternative in Qatar. Given these considerations, asciminib emerges as a promising therapeutic option for patients with CP-CML requiring third-line treatment, striking a balance between efficacy, safety, and economic feasibility within the local healthcare framework.<\/jats:p>","DOI":"10.1007\/s12672-025-03759-7","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:14:54Z","timestamp":1761228894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar"],"prefix":"10.1007","volume":"16","author":[{"given":"Rola","family":"Ghasoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"El Akiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Ellahie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"3759_CR1","unstructured":"European Public Assessment Report: Scemblix (asciminib). 2022(a). European Medicines Agency. https:\/\/yaorongyun-enterprise-data.oss-cn-shanghai.aliyuncs.com\/EuropeanUnion\/documents\/other\/005605\/scemblix-epar-public-assessment-report_en.pdf. Accessed 19 Feb 2025."},{"key":"3759_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdu490.","journal-title":"Ann Oncol"},{"key":"3759_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O\u2019Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 2012;97:1029\u201335. https:\/\/doi.org\/10.3324\/haematol.2011.056721.","journal-title":"Haematologica"},{"key":"3759_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392\u201399. https:\/\/doi.org\/10.1182\/blood-2015-06-648667.","journal-title":"Blood"},{"key":"3759_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580759","volume":"10","author":"Q Lin","year":"2020","unstructured":"Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H, et al. Global, regional, and national burden of chronic myeloid Leukemia, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:580759. https:\/\/doi.org\/10.3389\/fonc.2020.580759.","journal-title":"Front Oncol"},{"key":"3759_CR6","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1182\/blood-2019-126622","volume":"134","author":"MA Yassin","year":"2019","unstructured":"Yassin MA, Abdulla MAJ, Chandra P, Aldapt MA. Chronic myeloid leukemia in adolescents and young adults: a single institute experience. Blood. 2019;134:5915\u201315. https:\/\/doi.org\/10.1182\/blood-2019-126622.","journal-title":"Blood"},{"key":"3759_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1159\/000539982","volume":"102","author":"MAJ Abdulla","year":"2024","unstructured":"Abdulla MAJ, Aldapt MB, Chandra P, El Akiki S, Alshurafa A, Nashwan AJ, Fernyhough LJ, Sardar S, Chapra A, Yassin MA. Chronic myeloid leukemia in adolescents and young adults: clinicopathological variables and outcomes. Oncology. 2024;102:1018\u201328. https:\/\/doi.org\/10.1159\/000539982.","journal-title":"Oncology"},{"key":"3759_CR8","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/cancers16112114","volume":"16","author":"G Saglio","year":"2024","unstructured":"Saglio G, Yassin M, Alhuraiji A, Lal A, Alam A, Khan F, Khadada F, Osman H, Elkonaissi I, Marashi M, Abuhaleeqa M, Al-Khabori M, Pandita R, Al-Kindi S, Bahzad S, Daou D, Al Qudah Y. Current status and management of chronic myeloid leukemia in the Gulf region: survey results and expert opinion. Cancers. 2024;16:2114. https:\/\/doi.org\/10.3390\/cancers16112114.","journal-title":"Cancers"},{"key":"3759_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502. https:\/\/doi.org\/10.1038\/s41375-020-0842-9.","journal-title":"Leukemia"},{"key":"3759_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.diabres.2009.02.003","volume":"84","author":"A Bener","year":"2009","unstructured":"Bener A, Zirie M, Janahi IM, Al-Hamaq AO, Musallam M, Wareham NJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. Diabetes Res Clin Pract. 2009;84:99\u2013106. https:\/\/doi.org\/10.1016\/j.diabres.2009.02.003.","journal-title":"Diabetes Res Clin Pract"},{"key":"3759_CR11","unstructured":"World Health Organization Noncommunicable Diseases Country Profiles. 2018.\u00a0\u00a0Accessed 2 Feb 2025. https:\/\/iris.who.int\/handle\/10665\/274512"},{"key":"3759_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1025392","volume":"9","author":"K Ahmed","year":"2022","unstructured":"Ahmed K, Kaddoura R, Yassin MA. A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia. Front Med. 2022;9:1025392. https:\/\/doi.org\/10.3389\/fmed.2022.1025392.","journal-title":"Front Med"},{"key":"3759_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023;13:58. https:\/\/doi.org\/10.1038\/s41408-023-00823-9.","journal-title":"Blood Cancer J"},{"key":"3759_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221150305","volume":"14","author":"E Atallah","year":"2023","unstructured":"Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with \u2a7e2 tyrosine kinase inhibitors: a systematic literature review. Ther Adv Hematol. 2023;14:20406207221150305. https:\/\/doi.org\/10.1177\/20406207221150305.","journal-title":"Ther Adv Hematol"},{"key":"3759_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1163137","volume":"10","author":"R Kaddoura","year":"2023","unstructured":"Kaddoura R, Dabdoob WA, Ahmed K, Yassin MA. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. Front Med. 2023;10:1163137. https:\/\/doi.org\/10.3389\/fmed.2023.1163137.","journal-title":"Front Med"},{"key":"3759_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4236\/ijcm.2015.63023","volume":"06","author":"A Goodman","year":"2015","unstructured":"Goodman A. The development of the Qatar healthcare system: a review of the literature. IJCM. 2015;06:177\u201385. https:\/\/doi.org\/10.4236\/ijcm.2015.63023.","journal-title":"IJCM"},{"key":"3759_CR17","doi-asserted-by":"publisher","first-page":"107327482110384","DOI":"10.1177\/10732748211038429","volume":"28","author":"MAJ Abdulla","year":"2021","unstructured":"Abdulla MAJ, Chandra P, Akiki SE, Aldapt MB, Sardar S, Chapra A, Nashwan AJ, Sorio C, Tomasello L, Boni C, Yassin MA. Clinicopathological variables and outcome in chronic myeloid leukemia associated with BCR-ABL1 transcript type and body weight: an outcome of European leukemia net project. Cancer Control. 2021;28:10732748211038429. https:\/\/doi.org\/10.1177\/10732748211038429.","journal-title":"Cancer Control"},{"key":"3759_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ccr3.3738","volume":"9","author":"MA Yassin","year":"2021","unstructured":"Yassin MA, Kassem N, Ghassoub R. How i treat obesity and obesity related surgery in patients with chronic myeloid leukemia: an outcome of an ELN project. Clin Case Rep. 2021;9:1228\u201334. https:\/\/doi.org\/10.1002\/ccr3.3738.","journal-title":"Clin Case Rep"},{"key":"3759_CR19","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(13)62120-0.","journal-title":"Lancet"},{"key":"3759_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"key":"3759_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1385\u2013415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047.","journal-title":"J Natl Compr Canc Netw"},{"key":"3759_CR22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Br\u00fcmmendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337. https:\/\/doi.org\/10.1038\/s41375-020-0915-9.","journal-title":"Leukemia"},{"key":"3759_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"G Smith","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al. A British society for haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191:171\u201393. https:\/\/doi.org\/10.1111\/bjh.16971.","journal-title":"Br J Haematol"},{"key":"3759_CR24","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic Myeloid Leukemia Version 3. 2025.\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf.Accessed 14 Feb 2025"},{"key":"3759_CR25","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37:2150\u201367. https:\/\/doi.org\/10.1038\/s41375-023-02048-y.","journal-title":"Leukemia"},{"key":"3759_CR26","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"S Soverini","year":"2005","unstructured":"Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to Imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol. 2005;23:4100\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.05.531.","journal-title":"J Clin Oncol"},{"key":"3759_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. blood. 2011;118:1208\u201315. https:\/\/doi.org\/10.1182\/blood-2010-12-326405.","journal-title":"blood"},{"key":"3759_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1376","volume":"6","author":"C Benjamin","year":"2023","unstructured":"Benjamin C, Murugan S, Hoosen S, Rapiti N. Chronic myeloid leukemia kinase domain mutations: a retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa. Health Sci Rep. 2023;6:e1376. https:\/\/doi.org\/10.1002\/hsr2.1376.","journal-title":"Health Sci Rep"},{"key":"3759_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:43\u201369. https:\/\/doi.org\/10.6004\/jnccn.2024.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"3759_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5339\/connect.2014.13","volume":"2014","author":"NI Al-Dewik","year":"2014","unstructured":"Al-Dewik NI, Jewell AP, Yassin MA, El-Ayoubi HR, Morsi HM. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with Imatinib mesylate in the state of Qatar. QSci Connect. 2014;2014:1\u201313. https:\/\/doi.org\/10.5339\/connect.2014.13.","journal-title":"QSci Connect"},{"key":"3759_CR31","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1182\/blood-2022-165501","volume":"140","author":"AJ Innes","year":"2022","unstructured":"Innes AJ, Hayden C, Orovboni V, Rees D. Real-world experience of asciminib: factors associated with response. Blood. 2022;140:6796\u20137. https:\/\/doi.org\/10.1182\/blood-2022-165501.","journal-title":"Blood"},{"key":"3759_CR32","unstructured":"IQWIG. 2023. https:\/\/www.g-ba.de\/downloads\/92-975-6104\/2022-10-01_Bewertung-Therapiekosten-Patientenzahlen-IQWiG_Asciminib_D-865.pdf. Accessed 20 Feb 2025."},{"key":"3759_CR33","unstructured":"Leukemia and Lymphoma Society. Treatment-Free Remission for Chronic Myeloid Leukemia Patients. 2018.\u00a0https:\/\/www.lls.org\/sites\/default\/files\/2021-05\/FS34_Treatment_Free_Remission2018.pdf. Accessed 3 Mar 2025."},{"key":"3759_CR34","unstructured":"FDA. Highlights of prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215358s009lbl.pdf. Accessed 3 Mar 2025."},{"key":"3759_CR35","unstructured":"European Medicines Agency. European Medicines Agency. Scemblix: EPAR \u2013 Product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/scemblix-epar-product-information_en.pdfURL. Accessed 19 Feb 2025."},{"key":"3759_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","volume":"63","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, et al. Clinical pharmacology of asciminib: a review. Clin Pharmacokinet. 2024;63:1513\u201328. https:\/\/doi.org\/10.1007\/s40262-024-01428-6.","journal-title":"Clin Pharmacokinet"},{"key":"3759_CR37","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garc\u00eda-Guti\u00e9rrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, B\u00e9doucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341. https:\/\/doi.org\/10.1182\/blood.2020009984.","journal-title":"Blood"},{"key":"3759_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc\u00eda-Guti\u00e9rrez V, Kapoor S, Allepuz A, Quenet S, B\u00e9doucha V, Mauro MJ. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326. https:\/\/doi.org\/10.1038\/s41375-023-01829-9.","journal-title":"Leukemia"},{"key":"3759_CR39","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u2265 1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522\u201333. https:\/\/doi.org\/10.1038\/s41375-024-02278-8.","journal-title":"Leukemia"},{"key":"3759_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","volume":"14","author":"I Rinaldi","year":"2023","unstructured":"Rinaldi I, Winston K. Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. J Blood Med. 2023;14:261\u201377. https:\/\/doi.org\/10.2147\/JBM.S382090.","journal-title":"J Blood Med"},{"key":"3759_CR41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D R\u00e9a","year":"2023","unstructured":"R\u00e9a D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D\u2019Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023;37:1060\u201367. https:\/\/doi.org\/10.1038\/s41375-023-01888-y.","journal-title":"Leukemia"},{"key":"3759_CR42","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C, ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351. https:\/\/doi.org\/10.1093\/annonc\/mdx219.","journal-title":"Ann Oncol"},{"key":"3759_CR43","unstructured":"National Institute for Health and Care Excellence. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813). NICE. 2023. Accessed 14 Feb 2025. https:\/\/www.nice.org.uk\/guidance\/ta813"},{"key":"3759_CR44","unstructured":"BC Cancer. BC Cancer Protocol Summary for Treatment of Chronic Myeloid Leukemia using Asciminib. http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Leukemia-BMT\/LKCMLA_Protocol.pdf. Accessed 17 Feb 2025."},{"key":"3759_CR45","unstructured":"eviQ C, Institute NSW. Chronic myeloid leukaemia \u2013 Asciminib. https:\/\/www.eviq.org.au\/haematology-and-bmt\/leukaemias\/chronic-myeloid-leukaemia\/4283-chronic-myeloid-leukaemia-asciminib. Accessed 14 Feb 2025."},{"key":"3759_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bulcan.2019.05.011","volume":"107","author":"JM Cayuela","year":"2020","unstructured":"Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, R\u00e9a D. Pour La France intergroupe des Leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) et Le groupe des biologistes mol\u00e9culaires des h\u00e9mopathies malignes (GBMHM). Recommandations du France intergroupe des Leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) pour l\u2019examen des mutations du Domaine kinase de BCR-ABL1 Dans La Leuc\u00e9mie my\u00e9lo\u00efde chronique [Recommendations from the French CML study group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid Leukemia]. Bull Cancer. 2020;107:113\u201328. https:\/\/doi.org\/10.1016\/j.bulcan.2019.05.011.","journal-title":"Bull Cancer"},{"key":"3759_CR47","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813. https:\/\/doi.org\/10.1038\/s41375-025-02664-w.","journal-title":"Leukemia"},{"key":"3759_CR48","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/cancers15041045","volume":"15","author":"L P\u00e9rez-Lamas","year":"2023","unstructured":"P\u00e9rez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, P\u00e9rez L\u00f3pez R, Ruiz Nu\u00f1o C, De Las Heras N, Mora Caster\u00e1 E, L\u00f3pez Mar\u00edn J, Segura D\u00edaz A, G\u00f3mez V, Tenza PV, Pacho SM, Go\u00f1i JAV, Moreno Vega M, Alvarez-Larr\u00e1n A, Cort\u00e9s M, Encinas MP, Mastell PC, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Blanco VL, de Paz R, Coll PA, Fern\u00e1ndez JM, Casado FL, Alonso-Dom\u00ednguez MJ, Arance AMM, Cuenca SA, Jim\u00e9nez-Velasco A, Prendes OS, Santaliestra M, Chulvi LMM. Hern\u00e1ndez-Boluda CZ, Garc\u00eda-Guti\u00e9rrez V.Toxicity of asciminib in real clinical practice: analysis of side effects and Cross-Toxicity with tyrosine kinase inhibitors. Cancers. 2023;15:1045. https:\/\/doi.org\/10.3390\/cancers15041045.","journal-title":"Cancers"},{"key":"3759_CR49","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood-2023-181789","volume":"142","author":"E Kuzmina","year":"2023","unstructured":"Kuzmina E, Chelysheva E, Lomaia E, Morozova VE. The updated results of asciminib Managed-Access program (MAP) in patients with chronic myeloid leukemia in Russia. Blood. 2023;142:1803\u201303. https:\/\/doi.org\/10.1182\/blood-2023-181789.","journal-title":"Blood"},{"key":"3759_CR50","doi-asserted-by":"publisher","first-page":"9635","DOI":"10.1182\/blood-2022-157991","volume":"140","author":"M Breccia","year":"2022","unstructured":"Breccia M, Turkina A, Boquimpani C, Chuah C. ASC4OPT: a phase 3b open-label optimization study of oral asciminib in chronic myelogenous leukemia in chronic phase previously treated with 2 or more tyrosine kinase inhibitors. Blood. 2022;140:9635\u20136. https:\/\/doi.org\/10.1182\/blood-2022-157991.","journal-title":"Blood"},{"key":"3759_CR51","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/01.HS9.0000845720.69342.77","volume":"6","author":"CC Kockerols","year":"2022","unstructured":"Kockerols CC, Janssen JJ, Blijlevens NM, Klein KS. P709: clinical outcome of asciminib treatment in a real-world multi-resistant CML patient population. HemaSphere. 2022;6:604\u20135. https:\/\/doi.org\/10.1097\/01.HS9.0000845720.69342.77.","journal-title":"HemaSphere"},{"key":"3759_CR52","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1182\/blood-2022-163221","volume":"140","author":"LCY Chee","year":"2022","unstructured":"Chee LCY, Lee N, Grigg A, Chen M. Clinical outcomes of chronic myeloid leukaemia (CML) patients on asciminib through the managed access program (MAP) in Australia. Blood. 2022;140:6800\u201302. https:\/\/doi.org\/10.1182\/blood-2022-163221.","journal-title":"Blood"},{"key":"3759_CR53","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman SM, Park HJ, Druker JB, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse GK, Lang F, Kim DW. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"N Engl J Med"},{"key":"3759_CR54","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/13696998.2023.2234776","volume":"26","author":"JE Cortes","year":"2023","unstructured":"Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. Health care resource utilization in 3L\u2009+\u2009patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. Med Econ. 2023;26:915\u201323. https:\/\/doi.org\/10.1080\/13696998.2023.2234776.","journal-title":"Med Econ"},{"key":"3759_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000505486","volume":"98","author":"G Novo","year":"2020","unstructured":"Novo G, Di Lisi D, Bronte E, Macaione F, Accurso V, Badalamenti G, Rinaldi G, Siragusa S, Novo S, Russo A. Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience. Oncology. 2020;98:445\u201351. https:\/\/doi.org\/10.1159\/000505486.","journal-title":"Oncology"},{"key":"3759_CR56","unstructured":"Ministry of Public Health Qatar. Policy affairs, pricing, and registration. (n.d.). https:\/\/www.moph.gov.qa\/english\/departments\/policyaffairs\/pdc\/regnpricing\/Pages\/default.aspx. Accessed 4 Oct 2023."},{"key":"3759_CR57","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","volume":"74","author":"SM Hoy","year":"2014","unstructured":"Hoy SM. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2014;74:793\u2013806. https:\/\/doi.org\/10.1007\/s40265-014-0216-6.","journal-title":"Drugs"},{"key":"3759_CR58","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2022-157822","volume":"140","author":"JE Cortes","year":"2022","unstructured":"Cortes JE, Deininger MW, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Three-year update from the optic trial: a dose-optimization study of 3 starting doses of Ponatinib. Blood. 2022;140:1495\u20137. https:\/\/doi.org\/10.1182\/blood-2022-157822.","journal-title":"Blood"},{"key":"3759_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106690","volume":"111","author":"V Kota","year":"2021","unstructured":"Kota V, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2013positive leukemias. Leuk Res. 2021;111:106690. https:\/\/doi.org\/10.1016\/j.leukres.2021.106690.","journal-title":"Leuk Res"},{"issue":"15suppl","key":"3759_CR60","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2021.39.15_suppl.7039","volume":"39","author":"MW Deininger","year":"2021","unstructured":"Deininger MW, Br\u00fcmmendorf TH, Milojkovic D, Cervantes F. Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib. J Clin Oncol. 2021;39(15suppl):7039\u201339. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7039.","journal-title":"J Clin Oncol"},{"key":"3759_CR61","unstructured":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia Informe de Posici\u00f3n de la SEHH Asciminib en leucemia mieloide cr\u00f3nica (LMC). 2022. https:\/\/www.sehh.es\/publicaciones\/informes-de-posicion-de-la-sehh-ips\/125297-asciminib-en-leucemia-mieloide-cronica-lmc. Accessed 19 Feb 2025."},{"key":"3759_CR62","unstructured":"European Medicines Agency. Iclusig: EPAR \u2013 Public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/iclusig-epar-public-assessment-report_en.pdf. Accessed 6 Feb 2025."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03759-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03759-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03759-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:30:42Z","timestamp":1781613042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03759-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03759-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1959"}}